Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 2 August 2018, 21:00 HKT/SGT
Share:
    

Source: Lubrizol
Particle Sciences Receives Patent for Device to Deliver Medication to the Tympanic Membrane

CLEVELAND, Ohio, Aug 2, 2018 - (ACN Newswire) - The Lubrizol Corporation announces its LifeSciences and Particle Sciences businesses, have received a Notice of Allowance on a device for the delivery of medication to the ear-drum.

According to Rob Lee, president, Particle Sciences, "This latest patent is a clear-cut demonstration of our staff going beyond formulation to help our clients deliver a complete solution. It stems from work we did several years back and adds to the increasing pool of proprietary and public domain approaches Particle Sciences can offer its clients. This patent is aimed at providing targeted dosing to the tympanic membrane. We will be looking to partner with our clients on further development and utilization of this invention."

Particle Sciences, a Lubrizol LifeSciences company, is a leading drug delivery CDMO, an integrated provider of drug development services and manufacturing, and is FDA registered and DEA licensed. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nanoparticulates, drug-eluting devices, solid solutions, lyophilization and others.

Through a full range of formulation, analytic and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email info@particlesciences.com, or contact us at (610) 861-4701 for information.

Particle Sciences is part of Lubrizol Advanced Materials Inc.

About Lubrizol LifeSciences
Lubrizol LifeSciences is a preferred Contract Development and Manufacturing Organization (CDMO) partner for complex pharmaceuticals and high-end medical devices providing differentiated polymers and excipients, along with state-of-the-art design, development and manufacturing services to the healthcare industry.

About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is a market-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers' products while reducing their environmental impact. It is a leader at combining market insights with chemistry and application capabilities to deliver valuable solutions to customers in the global transportation, industrial and consumer markets. Lubrizol improves lives by acting as an essential partner in our customers' success, delivering efficiency, reliability or wellness to their end users. Technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care, personal care and skin care products and specialty materials encompassing polymer and coatings technologies, along with polymer-based pharmaceutical and medical device solutions.

With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 8,700 employees worldwide. Revenues for 2017 were $6.3 billion. For more information, visit Lubrizol.com.

Media Contact
Ben Patti
(216) 447-5827
Benjamin.patti@lubrizol.com
www.lubrizol.com/LifeSciences
www.particlesciences.com

###

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lubrizol via Globenewswire


Aug 2, 2018 21:00 HKT/SGT
Topic: Press release summary

http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Lubrizol
Mar 18, 2019 22:00 HKT/SGT
Lubrizol Completes Acquisition of Laboratoire Phenobio
Mar 6, 2019 23:30 HKT/SGT
Lubrizol Engineered Polymers Unveil Polymer Solutions for Automotive Interior Applications at PIAE 2019
Feb 26, 2019 21:30 HKT/SGT
Lubrizol Premium Partner at IQS Tech Fest 2019
Feb 21, 2019 00:00 HKT/SGT
Lubrizol Showcases Halogen-free Flame Retardant TPU Solutions at Cable 2019 Conference
Feb 7, 2019 21:30 HKT/SGT
Lubrizol Honors Lake County's Outstanding STEM Teacher Team
Feb 7, 2019 08:00 HKT/SGT
Lubrizol LifeSciences to Showcase New Medical Device Applications Lab at MDM West 2019
Feb 6, 2019 12:00 HKT/SGT
Lubrizol Introduces Non-Halogen FR Technology - Flame Retardant Performance Without Additives
Jan 31, 2019 23:00 HKT/SGT
Particle Sciences Partners with Encube Ethicals to Develop Novel Vaginal Rings
Jan 24, 2019 09:00 HKT/SGT
Lubrizol to Showcase New Coating Technologies at ECS 2019
Jan 10, 2019 10:00 HKT/SGT
Particle Sciences strengthens nanomilling offering with new API screening program
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: